GSK, ALXN, REGN And LLY, 4 Drugs Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 32 points (-0.2%) at 15,645 as of Thursday, Sept. 19, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,343 issues advancing vs. 1,599 declining with 112 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Amgen ( AMGN), down 1.3%, Celgene Corporation ( CELG), down 0.8%, Novartis ( NVS), down 0.7% and Gilead ( GILD), down 0.6%. A company within the industry that increased today was Bristol-Myers Squibb Company ( BMY), up 1.2%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry lower today. As of noon trading, GlaxoSmithKline is down $0.81 (-1.6%) to $50.46 on average volume. Thus far, 1.4 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $50.45-$51.18 after having opened the day at $51.15 as compared to the previous trading day's close of $51.27.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $125.3 billion and is part of the health care sector. Shares are up 17.6% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Mylan Badly Needs Help from FDA to Escape its Woes and Deliver These Key Drugs